Video

Urology Times 50 Innovations Series: Genetic testing for prostate cancer

Author(s):

Urology Times staff

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Veda N. Giri, MD, discusses the role genetic testing has played in a new era of prostate cancer therapeutics. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
Randy A. Vince Jr, MD, MS, answers a question during a Zoom video interview
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
DNA | Image Credit: © BillionPhotos.com - stock.adobe.com
Adri Durant, MD, and Mouneeb Choudry, MD, answer a question during a Zoom video interview
DNA helix | Image Credit: © Siarhei - stock.adobe.com
Related Content
Variants of unknown significance may adversely affect RARP outcomes
November 11th 2024

Variants of unknown significance may adversely affect RARP outcomes

Hannah Clarke
In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.
Genetic testing in prostate cancer is increasing over time, data suggests
November 11th 2024

Genetic testing in prostate cancer is increasing over time, data suggests

Hannah Clarke
“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.
Genomic risk model validated for prostate cancer risk prediction
November 6th 2024

Genomic risk model validated for prostate cancer risk prediction

Hannah Clarke
Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.
Circulating tumor cell count may serve as a prognostic biomarker in mHSPC
October 8th 2024

Circulating tumor cell count may serve as a prognostic biomarker in mHSPC

Hannah Clarke
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
NSD1/2 may serve as potential therapeutic targets in prostate cancer
September 11th 2024

NSD1/2 may serve as potential therapeutic targets in prostate cancer

Hannah Clarke
“NSD2 is a cancer specific collaborator of the androgen receptor that essentially rewires its activity to support prostate cancer development," says Abhijit Parolia, PhD,
Gene mutations associated with response to cisplatin-based chemotherapy in MIBC
September 3rd 2024

Gene mutations associated with response to cisplatin-based chemotherapy in MIBC

Hannah Clarke
Patients who had mutations in the ERCC2, ATM, or RB1 genes were more than 5 times more likely to achieve a pathologic complete response following cisplatin-based chemotherapy.
© 2024 MJH Life Sciences

All rights reserved.